Interpace Diagnostics Group (IDXG) versus MAXIMUS (MMS) Head to Head Analysis

Interpace Diagnostics Group (NASDAQ: IDXG) and MAXIMUS (NYSE:MMS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Interpace Diagnostics Group and MAXIMUS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -6.33% -5.69% -3.06%
MAXIMUS 8.54% 23.97% 15.63%

Risk and Volatility

Interpace Diagnostics Group has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, MAXIMUS has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

5.7% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 94.9% of MAXIMUS shares are owned by institutional investors. 0.7% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 3.1% of MAXIMUS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

MAXIMUS pays an annual dividend of $0.18 per share and has a dividend yield of 0.3%. Interpace Diagnostics Group does not pay a dividend. MAXIMUS pays out 5.7% of its earnings in the form of a dividend.

Earnings and Valuation

This table compares Interpace Diagnostics Group and MAXIMUS’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $13.09 million 2.32 -$8.33 million $2.99 0.38
MAXIMUS $2.45 billion 1.86 $209.42 million $3.17 22.13

MAXIMUS has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than MAXIMUS, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Interpace Diagnostics Group and MAXIMUS, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 1 0 3.00
MAXIMUS 0 3 1 0 2.25

Interpace Diagnostics Group presently has a consensus target price of $5.00, indicating a potential upside of 342.48%. MAXIMUS has a consensus target price of $63.75, indicating a potential downside of 9.12%. Given Interpace Diagnostics Group’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Interpace Diagnostics Group is more favorable than MAXIMUS.

Summary

MAXIMUS beats Interpace Diagnostics Group on 10 of the 15 factors compared between the two stocks.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

About MAXIMUS

MAXIMUS, Inc. provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs. The Health Services segment provides a range of BPS, as well as related consulting services, for state, provincial and national government programs. The Human Services segment provides national, state and local human services agencies with a range of BPS and related consulting services for welfare-to-work, child support, higher education and K-12 special education programs.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply